9P Circulating tumour cells (CTCs) count and PD-L1 expression in untreated extensive small cell lung cancer patients treated in the REACTION trial, a phase II study of etoposide and cis/carboplatin with or without pembrolizumab (NCT02580994) / Menis, J.; Bironzo, P.; Radj, G.; Greillier, L.; Monnet, I.; Livi, L.; Young, R.; Decroisette, C.; Cloarec, N.; Robinet, G.; Schott, R.; Califano, R.; De Marinis, F.; Mauer, M.; Pochesci, A.; Silva, M.; Caramella, C.; Dingemans, A-M.; Dive, C.; Besse, B.. - In: ANNALS OF ONCOLOGY. - ISSN 0923-7534. - 31:(2020), p. S1420. [10.1016/j.annonc.2020.10.494]
9P Circulating tumour cells (CTCs) count and PD-L1 expression in untreated extensive small cell lung cancer patients treated in the REACTION trial, a phase II study of etoposide and cis/carboplatin with or without pembrolizumab (NCT02580994)
Silva, M.Membro del Collaboration Group
;
2020-01-01
File in questo prodotto:
Non ci sono file associati a questo prodotto.
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
